ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Abrocitinib (Primary)
- Indications Atopic dermatitis
- Focus Expanded access; Therapeutic Use
- Acronyms JADE-REAL
- Sponsors Pfizer
- 19 Jun 2024 Status changed from recruiting to completed.
- 07 Jul 2023 This trial has been completed in Austria, according to European Clinical Trials Database record.
- 05 Apr 2023 The trial has been discontinued in Greece, according to European Clinical Trials Database record.